GW Pharmaceuticals PLC – ADR (NASDAQ: GWPH)
Without any real catalyst, GW Pharmaceuticals soared on Tuesday June 2nd. GWPH opened at $114.08 and reached a high of $125.2; up $11.12 (+.09%) as seen in the chart below. This rally to $125.20 was just shy of their all time high of $126.78 which they reached on April 27th of this year. GWPH has a market cap of $2.36B, experienced a rough end to 2014. However, since January the stock has been in an uptrend.
One of GWPH competitors is Nemus Bioscience (OTCBB: NMUS). NMUS is currently trading at $3.15. For some strange reason, this stock hardly moved today whereas GWPH was up over $10. As it stands now, Nemus is not a strong competitor for the simple reason that they lack financing. GWPH already has their financing in place for future testing and developments.
Insys Therapeutics (NASDAQ: INSY) is another competitor in this space working with a cannabis oral solution for epilepsy patients. INSY is currently trading at $61.81 with a market cap of $2.21B. As shown in their chart below, they too are in a strong uptrend.
GW Pharmaceuticals Outlook
According to Investopedia, there are about 80 companies that have jumped on the medical cannabis space with it currently being legal for medicinal use in 23 states. Optimism abounds that the medical marijuana industry could reach $150-$200 billion. GW Pharmaceuticals is the best in breed in the medical marijuana sector.
Analysts on the street have given GWPH a mean target of $142 and a high target of $151.00
Most if not all of the sentiment for GWPH is bullish. As Zack’s mentions, the stock has a Zachs Rank of #1 or Strong Buy. Investors are happy with GWPH going up 15.2% in the past four weeks as of mid April and up 14% if the most recent four weeks, staying well above its 20 day Simple Moving Average.
What are your thoughts on GWPH? We would like to see how others view the future for Medicinal Marijuana and GWPH!
Let’s see if this positive trend continues.
GW Pharmaceuticals, a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines. It operates in three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. They primarily offers Sativex, an oromucosal spray for the treatment of multiple sclerosis symptoms, cancer pain, and neuropathic pain. It also focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. In addition, the company’s product pipeline includes an orphan childhood epilepsy program, as well as other product candidates in Phase I and II clinical development for the treatment of glioma, ulcerative colitis, type-2 diabetes, and schizophrenia. It has a strategic alliance with Otsuka Pharmaceutical Co., Ltd. The company operates in the United Kingdom, Europe, the United States, Canada, and Asia. GW Pharmaceuticals was founded seventeen years ago in 1998 and is based in Salisbury, the United Kingdom. Yahoo! Finance